Last reviewed · How we verify
Treatment of sickle cell disease (SCD) in adults
Approved treatments
- Oxbryta · Pfizer Inc.
Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity.
Clinical guidelines
- FDA label — any
OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults. - FDA label — any
OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of sickle cell disease (SCD) in adults patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of sickle cell disease (SCD) in adults treatment landscape brief
- Treatment of sickle cell disease (SCD) in adults treatment updates RSS
Frequently asked questions about Treatment of sickle cell disease (SCD) in adults
What drugs treat Treatment of sickle cell disease (SCD) in adults?
Tracked treatments include Oxbryta.
What is the treatment for Treatment of sickle cell disease (SCD) in adults?
Standard treatment for Treatment of sickle cell disease (SCD) in adults includes Oxbryta. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Treatment of sickle cell disease (SCD) in adults?
FDA label publishes guidelines for Treatment of sickle cell disease (SCD) in adults. 2 guideline references tracked.
Related
- Treatment landscape: Treatment of sickle cell disease (SCD) in adults patent cliff · Treatment of sickle cell disease (SCD) in adults CI report
- Treatment: Oxbryta · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing